Axitinib 阿西替尼
CAS 319460-85-0 MFCD09837898
化学结构图
SMILES: CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
化学属性
| Mol. Formula | C22H18N4OS |
|---|---|
| Mol. Weight | 386.47 |
| Density | 1.4 |
| Boiling Point | 668.9 |
| Melting Point | 226-228 |
| Appearance | white to off-white solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name | Axitinib |
|---|---|
| CAS Number | 319460-85-0 |
| Synonym | AG 013736 AG-013736 AG013736; AG 013736; AG-013736; Axitinib; Brand name: Inlyta. N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide |
| MDL Number | MFCD09837898 |
| Chemical Name Translation | 阿西替尼 |
| PubChem Substance ID | 329823767 |
| Formula | C22H18N4OS |
| IUPAC Name | (E)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide |
| InChIKey | RITAVMQDGBJQJZ-FMIVXFBMSA-N |
| InChI | InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+ |
| Canonical SMILES | O=C(NC)C1=CC=CC=C1SC2=CC3=C(C=C2)C(/C=C/C4=NC=CC=C4)=NN3 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- AN-AZ, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience, Kinase/Phosphatase Biology, Pfizer Compounds, Receptor Tyrosine Kinase Biology, Receptor Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGF)
- {SNA} AN-AZ, Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Diversification Ready Pharma-Developed Compounds, Kinase/Phosphatase Biology, Pfizer Compounds, Receptor Tyrosine Kinase Biology, Receptor Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGF), 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
产品应用
- Axitinib, also known as AG013736, is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. A xitinib has received FDA (27 January 2012), EMA (13 September 2012), MHRA (3 September 2012) and TGA (26 July 2012) approval for use as a treatment for renal cell carcinoma.
相关文献及参考
- Wasser, K., et al.: Eur. Radiol., 13, 80 (2003),
- Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ., Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother. Pharmacol. 65 , 563-570, (2010) 摘要
- Hu-Lowe DD, et al., Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 14 , 7272-7283, (2008)
- Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM., Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res. 69 , 4527-4536, (2009)
安全信息
GHS Symbol
- P273 Avoid release to the environment. 避免释放到环境中。
- H400 Verytoxictoaquaticlife 对水生生物毒性非常大。
- H302 Harmful if swallowed 吞食有害
- S60 This material and its container must be disposed of as hazardous waste 该物质及其容器必须作为危险废物处置；
- S61 Avoid release to the environment. Refer to special instructions/safety data sheet 避免释放到环境中，参考特别指示/安全收据说明书；
- R22 Harmful if swallowed 吞咽有害
- R50/53
京ICP备2020036287号